What the FDA labels say about taking them together
Gemfibrozil and repaglinide
Gemfibrozil's FDA label of April 10, 2026 names repaglinide in its contraindications section, and repaglinide's label names gemfibrozil too. The repaglinide label: “Gemfibrozil significantly increased repaglinide tablets exposures by 8.1 fold.”
Check it at the source: the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC); the repaglinide FDA label on DailyMed (effective May 2, 2025, Chartwell RX, LLC).
What does the gemfibrozil label say about repaglinide?
Gemfibrozil label, contraindicationsCombination therapy of gemfibrozil with repaglinide (see PRECAUTIONS ).
Gemfibrozil label, drug interactionsIn healthy volunteers, co-administration with gemfibrozil (600 mg twice daily for 3 days) resulted in an 8.1-fold (range 5.5- to 15.0- fold) higher repaglinide AUC and a 28.6-fold (range 18.5- to 80.1-fold) higher repaglinide plasma concentration 7 hours after the dose.
Gemfibrozil label, warningsCombination therapy of gemfibrozil with simvastatin or with repaglinide, which are OATP1B1 substrates, is contraindicated (see CONTRAINDICATIONS ).
Lopid label (Parke-Davis Div of Pfizer Inc, May 21, 2026), drug interactionsRepaglinide In healthy volunteers, co-administration with gemfibrozil (600 mg twice daily for 3 days) resulted in an 8.1-fold (range 5.5- to 15.0- fold) higher repaglinide AUC and a 28.6-fold (range 18.5- to 80.1-fold) higher repaglinide plasma concentration 7 hours after the dose.
Source: FDA drug label (Lopid, NDA018422), Parke-Davis Div of Pfizer Inc, effective May 21, 2026 (SPL set c48855b7-215e-453b-b3b1-a0f9dee7221f), via openFDA
Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed
What does the repaglinide label say about gemfibrozil?
Repaglinide label, contraindicationsCONTRAINDICATIONS Repaglinide tablets are contraindicated in patients with: Concomitant use of gemfibrozil [see Drug Interactions (7.1) ]. Known hypersensitivity to repaglinide or any inactive ingredients.
Repaglinide label, drug interactionsGemfibrozil Clinical Impact: Gemfibrozil significantly increased repaglinide tablets exposures by 8.1 fold. Intervention: Do not administer repaglinide tablets to patients receiving gemfibrozil [see ].
Source: FDA drug label (Repaglinide), Chartwell RX, LLC, effective May 2, 2025 (SPL set cb995e92-295e-4638-a064-978211f5afe1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Gemfibrozil | Repaglinide | |
|---|---|---|
| Labeled for | High cholesterol, Heart attack and coronary artery disease | Type 2 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.104 per tablet 600 mg tablet | $0.0987 per tablet 1 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once